1. Trang chủ >
  2. Y Tế - Sức Khỏe >
  3. Y học thưởng thức >

Appendix 1. Author Relationships With Industry And Other Entities (Relevant)— 2011 Accf/Aha Guideline For Coronary Artery Bypass Graft Surgery

Bạn đang xem bản rút gọn của tài liệu. Xem và tải ngay bản đầy đủ của tài liệu tại đây (1.51 MB, 88 trang )


Hillis et al.

2011 ACCF/AHA CABG Guideline



JACC Vol. 58, No. 24, 2011

December 6, 2011:e123–210



Committee

Member



Employer/Title



Speaker’s

Bureau



Consultant



John A. Bittl



Ocala Heart

Institute

Munroe

Regional

Medical

Center—

Interventional

Cardiologist



None



Charles R.

Bridges



University of

Pennsylvania

Medical

Center—Chief

of

Cardiothoracic

Surgery











Baxter

BioSurgery†

Zymogenetics



None







Bayer

Pharmaceuticals



Ownership/

Partnership/

Principal



Personal

Research



Institutional,

Organizational, or

Other Financial

Benefit



Expert

Witness



None



None



None



None



None



None



None























Plaintiff,

alleged mitral

valve

dysfunction,

2009

Defendant,

retinal artery

occlusion

(stroke) after

CABG, 2009

Defendant,

timely insertion

of IABP after

CABG, 2009

Defendant,

timely transport

after acute

aortic

dissection,

2009

Plaintiff,

unexpected

intra-abdominal

hemorrhage

and death after

AVR, 2009



e205



Voting

Recusals

by Section

Numbers*

None



2.2.3

4.1

4.2

5.2.6



John G. Byrne



Vanderbilt

University

Medical Center:

Division of

Cardiac

Surgery—

Chairman of

Cardiac Surgery



None



None



None



None



None



None



None



Joaquin E.

Cigarroa



Oregon Health and

Science

University—

Associate

Professor of

Medicine



None



None



None



None



None



None



None



Verdi J.

DiSesa



John Hopkins

Hospital,

Division of

Cardiac

Surgery—Clinical

Associate



None



None



None



None



None



None



None



Loren F.

Hiratzka



Cardiac, Vascular

and Thoracic

Surgeons,

Inc.—Medical

Director of

Cardiac Surgery



None



None



None



None



None



None



None



Adolph M.

Hutter



Massachusetts

General

Hospital—

Professor of

Medicine



None



None



None



None



None



None



None



Michael E.

Jessen



UT Southwestern

Medical

Center—

Professor of

Cardiothoracic

Surgery







None



None



None



None



None



2.1.8



Quest Medical†



Downloaded From: http://content.onlinejacc.org/ on 02/28/2013



e206



Committee

Member



Hillis et al.

2011 ACCF/AHA CABG Guideline



Employer/Title



JACC Vol. 58, No. 24, 2011

December 6, 2011:e123–210



Speaker’s

Bureau



Consultant



Ownership/

Partnership/

Principal



Personal

Research



Institutional,

Organizational, or

Other Financial

Benefit



Expert

Witness



Voting

Recusals

by Section

Numbers*



Ellen C.

Keeley



University of

Virginia—

Associate

Professor of

Internal

Medicine



None



None



None



None



None



None



Stephen J.

Lahey



University of

Connecticut—

Professor and

Chief of

Cardiothoracic

Surgery



None



None



None



None



None







Richard A.

Lange



University of Texas

Health Science

Center at San

Antonio—

Professor of

Medicine



None



None



None



None



None



None



None



Martin J.

London



University of

None

California San

Francisco,

Veterans Affairs

Medical

Center—Professor

of Clinical

Anesthesia



None



None



None



None



None



None



Michael J.

Mack



The Heart Hospital

Baylor Plano—

Cardiovascular

Surgery,

Medical Director



None



None



None



None



None



2.1.3

2.2.1

5.2.1.1

5.2.1.2



None



None



None



None



None



None



Marquett

Medtronic



None



None







None



None



2.1.3

2.2.1

2.2.2



Edwards

Lifesciences

Medtronic



None



None



None



None



None



2.2.2

5.2.1.1

5.2.1.2













Cordis

Marquett

Medtronic

Edwards

Lifesciences†



Defendant,

mitral valve

replacement,

2009



None



None



Manesh R.

Patel



Duke University

None

Medical

Center—Associate

Professor of

Medicine



John D.

Puskas



Emory University/

Emory

Healthcare—

Chief of Cardiac

Surgery







Joseph F.

Sabik



Cleveland Clinic

Foundation—

Professor of

Surgery







Ola Selnes



John Hopkins

Hospital,

Department of

Neurology—

Professor of

Neurology



None



None



None



None



None



None



None



David M.

Shahian



Massachusetts

General

Hospital—

Professor of

Surgery



None



None



None



None



None



None



None



Jeffrey C.

Trost



John Hopkins

School of

Medicine—

Assistant

Professor of

Medicine



None



None



None







None



None



2.1.7

4.10

4.10.1

4.10.2

4.10.3

5.2.1.1.1

5.2.1.1.2















Downloaded From: http://content.onlinejacc.org/ on 02/28/2013



Marquett‡

Medtronic‡



Toshiba‡



Hillis et al.

2011 ACCF/AHA CABG Guideline



JACC Vol. 58, No. 24, 2011

December 6, 2011:e123–210



Committee

Member

Michael D.

Winniford



Employer/Title

University of

Mississippi

Medical

Center—

Professor of

Medicine



Speaker’s

Bureau



Consultant

None



None



Ownership/

Partnership/

Principal

None



Personal

Research



Institutional,

Organizational, or

Other Financial

Benefit



None



None



e207



Voting

Recusals

by Section

Numbers*



Expert

Witness

None



None



This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated

in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the

time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of Ն5% of the voting stock or share of the business entity, or ownership of

Ն$10,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that

exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted.

According to the ACCF/AHA, a person has a relevant relationship IF: (a) The relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed

in the document; or (b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the

document; or (c) the person or a member of the person’s household, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed

in the document. *Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply. †No financial

benefit. ‡Significant relationship.

AVR indicates aortic valve replacement; CABG, coronary artery bypass graft surgery; and IABP, intraaortic balloon pump.



APPENDIX 2. REVIEWER RELATIONSHIPS WITH INDUSTRY AND OTHER ENTITIES (RELEVANT)—

2011 ACCF/AHA GUIDELINE FOR CORONARY ARTERY BYPASS GRAFT SURGERY



Speaker’s

Bureau



Consultant



Ownership/

Partnership/

Principal



Personal

Research



Peer Reviewer



Representation



Robert Guyton



Official Reviewer—

ACCF/AHA Task

Force on

Practice

Guidelines



None



None



None







Jeffrey Jacobs



Official Reviewer—

ACCF/AHA Task

Force on Data

Standards



None



None



None



None



L. Kristin

Newby



Official Reviewer—

AHA







None



None







Eric D.

Peterson



Official Reviewer—

ACCF/AHA Task

Force on

Performance

Measures







Richard J.

Shemin



Official Reviewer—

AHA







Hector Ventura



Official Reviewer—

ACCF Board of

Governors



None



Thad F. Waites



Official Reviewer—

ACCF Board of

Trustees



None



T. Bruce

Ferguson, Jr.



Organizational

Reviewer—STS



Stephen E.

Fremes



Organizational

Reviewer—AATS



AstraZeneca







AstraZeneca



None



None











Edwards

Lifesciences



None



Edwards

Lifesciences



Institutional,

Organizational, or

Other Financial

Benefit



Expert

Witness



None



None



None



None



Eli Lilly*

GlaxoSmithKline†



None



None



BMS/sanofiaventis†

Eli Lilly†



None



None



None



None



None



None



None



None



None



None



None



None



None



None



None



None



None



None



None



None



None



None



None



None



None



Merck













Actelion

Gilead







Defendant,

leaking thoracic

aortic aneurysm,

2009

Defendant, aortic

dissection, 2009



Colleen G.

Koch



Organizational

Reviewer—SCA



None



None



None



None



None



None



Harold L. Lazar



Organizational

Reviewer—AATS



None



None



None



None



None



None



Walter H.

Merrill



Organizational

Reviewer—STS



None



None



None



None



None



None



Downloaded From: http://content.onlinejacc.org/ on 02/28/2013



e208



Hillis et al.

2011 ACCF/AHA CABG Guideline



Peer Reviewer



Representation

Organizational

Reviewer—SCA



None



Joseph S.

Alpert



Content Reviewer







Robert M.

Califf



Content Reviewer

















Content Reviewer



Speaker’s

Bureau



Consultant



Stanton K.

Shernan



Robbin G.

Cohen



JACC Vol. 58, No. 24, 2011

December 6, 2011:e123–210







Philips

Healthcare



Ownership/

Partnership/

Principal



Personal

Research

None



None







None



None



None



None



None







None



None



None



AstraZeneca

Daiichi-Sankyo

GlaxoSmithKline

Medtronic

Sanofi-aventis



None



None









None



Expert

Witness



None



Bayer

Sanofi-aventis



None



Institutional,

Organizational, or

Other Financial

Benefit



None



Eli Lilly†

Bayer



None











Defendant, death

after minimally

invasive heart

surgery, 2011

Defendant,

diagnosis of aortic

dissection, 2010

Plaintiff, renal

failure and

Aprotinin, 2010



None



None







Merck



None







None



None







Medtronic



None



None



None



None



None



None







None



None



None



None



None



None



Content Reviewer



None



None



None







Anthony P.

Furnary



Content

Reviewer—ACCF

Surgeons’

Scientific

Council



None



None



None



None



Valentin Fuster



Content Reviewer



None



None



None



None



None



None



John W.

Hirshfeld, Jr.



Content Reviewer







GlaxoSmithKline



None



None



None



None



None



Judith S.

Hochman



Content

Reviewer—

ACCF/AHA Task

Force on

Practice

Guidelines







Eli Lilly

GlaxoSmithKline



None



None



None



None



None







James L.

Januzzi, Jr.



Content Reviewer







Roche



None



None







None



None



Frederick G.

Kushner



Content

Reviewer—Vice

Chair, 2012

STEMI Guideline

Writing

Committee



None



None



None



None



None



None



Glenn Levine



Content Review—

Chair, 2011 PCI

Guideline

Writing

Committee



None



None



None



None



None



None



Mark A.

Creager



AstraZeneca

Genzyme

Merck

Roche

Vascutek



Plaintiff,

communication of

echocardiography

results, 2010



Content

Reviewer—

ACCF/AHA Task

Force on

Practice

Guidelines







Steven M.

Ettinger



Content Review—

ACCF/AHA Task

Force on

Practice

Guidelines



None



David P. Faxon



Content Reviewer







Kirsten E.

Fleischmann



Content Reviewer



Lee Fleisher













Sanofi-aventis



Downloaded From: http://content.onlinejacc.org/ on 02/28/2013



Pfizer



Roche







AstraZeneca†



None



Plaintiff, Fasudil

Development:

Asahi Pharma v

Actelion, 2010



Defendant, cath

vascular access

site complication,

2009







Defendant,

perioperative

stroke, 2009







Defendant, Bayer

Corp. Trasylol

litigation, 2009 to

2011



Xem Thêm
Tải bản đầy đủ (.pdf) (88 trang)

×